Currently, there are 54.58M common shares owned by the public and among those 47.93M shares have been available to trade.
The company’s stock has a 5-day price change of -79.48% and -73.13% over the past three months. MRNS shares are trading -96.56% year to date (YTD), with the 12-month market performance down to -94.40% lower. It has a 12-month low price of $0.26 and touched a high of $11.26 over the same period. MRNS has an average intraday trading volume of 1.93 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -75.77%, -75.36%, and -90.49% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Marinus Pharmaceuticals Inc (NASDAQ: MRNS) shares accounts for 70.73% of the company’s 54.58M shares outstanding.
It has a market capitalization of $20.57M and a beta (3y monthly) value of 1.17. The earnings-per-share (ttm) stands at -$2.66. Price movements for the stock have been influenced by the stock’s volatility, which stands at 40.79% over the week and 14.66% over the month.
Earnings per share for the fiscal year are expected to increase by 26.21%, and 63.83% over the next financial year. EPS should grow at an annualized rate of 20.00% over the next five years, compared to 6.04% over the past 5-year period.
Looking at the support for the MRNS, a number of firms have released research notes about the stock. Oppenheimer stated their Outperform rating for the stock in a research note on September 23, 2024, with the firm’s price target at $6. Robert W. Baird was of a view on April 16, 2024 that the stock is Neutral, while RBC Capital Mkts gave the stock Sector Perform rating on April 15, 2024, issuing a price target of $24- $3. Oppenheimer on their part issued Perform rating on August 11, 2023.
